Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY1834845 in Healthy Males and Psoriasis Patients
NCT03493269Phase 1Completed
- Sponsor
- Bayer
- Start
- Apr 2018
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zabedosertib in psoriasis (4 arms), sponsored by Bayer. Primary endpoints: Frequency of treatment-emergent adverse events at 84 days, Severity of treatment-emergent adverse events at 84 days and 4 more. Started Apr 2018; status: completed.
02
Drugs
zabedosertib
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT03493269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03493269.